Core Viewpoint - Hangzhou Shenluo Medical Technology Co., Ltd. has completed a multi-hundred million RMB Series C financing round, led by Junlian Capital, with participation from existing shareholders including OrbiMed, Boyuan Capital, and Guotou Chuanghe [2]. Company Introduction - Hangzhou Shenluo Medical Technology Co., Ltd. is engaged in the research and development of medical devices related to neuroregulation and brain-computer interfaces, headquartered in Hangzhou, Zhejiang Province [2]. Product and Technology Overview - The company focuses on the development and commercialization of implantable neurostimulation devices and brain-computer interface technologies [2]. 1. **Spinal Cord Stimulation (SCS) System**: Approved by the National Medical Products Administration (NMPA) for chronic pain management, launched in early 2026 [2]. 2. **Peripheral Nerve Stimulation (PNS) System**: Currently in the registration application stage for peripheral nerve regulation treatments [3]. 3. **Tibial Nerve Stimulation (TNS) System**: Targets neuroregulation for urinary function-related diseases, part of the company's wireless micro-neuroregulation technology platform [4]. 4. **Brain-Computer Interface Technology**: Developing a closed-loop brain-computer interface system for applications in neural function recovery, including spinal cord injuries [7]. 5. **Sublingual Nerve Stimulation System**: Under development for the treatment of obstructive sleep apnea [8]. Product Registration Status - The company has received multiple medical device registration certificates from the National Medical Products Administration, including: - Spinal Cord Stimulation External Controller - Implantable Spinal Cord Stimulation Electrodes - Test Stimulator - Patient Controller for Spinal Cord Stimulation [9]. Financing History - The financing history includes: - March 2026: Series C round, amount undisclosed, led by Chengdu Junrongkang Venture Capital [10]. - April 2024: Series B+ round, multi-hundred million RMB, led by OrbiMed [10]. - October 2022: Series B round, approximately hundred million RMB, led by Guotou Chuanghe [10]. - January 2022: Series A round, multi-million RMB, led by Bodin Capital [10]. Patent Situation - The company holds several authorized patents related to neurostimulation devices and methods, including: - Manufacturing methods for stimulation electrodes - Control methods for electrical stimulation devices - Wireless power supply devices for neurostimulators [12].

Group 1: AI in Medical Technology - The introduction of the "Qiguang AI OCT Base Model" by Weiguang Medical marks the entry of intravascular imaging into the "large model" era, integrating various diagnostic information into treatment strategies [3] - Jitai Technology launched the world's first AI-driven nano delivery platform, NanoForge, which utilizes quantum chemistry and molecular dynamics simulations to optimize lipid formulations for drug delivery [5][7] - The AI-assisted diagnostic system for coronary CTA and plaque analysis developed by Shukun Technology has received FDA 510(k) certification, making it the only company with comprehensive AI diagnostic capabilities for heart and brain [15] Group 2: Innovative Treatments and Clinical Applications - Weisheng Pharmaceutical's drug Palopegteriparatide has been approved for treating adult chronic hypoparathyroidism, filling a significant gap in hormone replacement therapy in China [9][11] - The first sublingual nerve stimulation implantation surgery in China was successfully completed, showcasing advancements in neurointerface technology for treating sleep apnea [13] - Lingyi Biotech has initiated Phase II clinical trials for LY-M001, the first AAV gene therapy for Type I Gaucher disease in China, demonstrating promising safety and efficacy [22] Group 3: Investment Landscape in Healthcare - Sequoia China has invested in over 200 healthcare companies with distinct technological features and high growth potential, covering various sectors including innovative drugs and medical devices, with more than 45 companies having completed IPOs [24]

Group 1 - The first sublingual nerve stimulation implant surgery in China was completed, marking a significant advancement in the treatment of obstructive sleep apnea (OSA) [1] - The surgery was performed by a multidisciplinary team, resulting in a notable reduction in apnea episodes and improvement in sleep quality for the patient [1] - This procedure represents a new direction in clinical applications of neural interfaces, potentially driving the development of sleep medicine, wearable monitoring, and rehabilitation management industries [1] Group 2 - Haizheng Pharmaceutical signed an exclusive licensing and strategic cooperation agreement with Aixin Dawei to introduce the first-in-class small molecule prodrug AST-3424 in China [2] - The collaboration aims to enhance Haizheng's innovative drug portfolio and leverage Aixin Dawei's promising research pipeline, potentially accelerating the introduction of new cancer treatment options [2] Group 3 - Renfu Pharmaceutical's subsidiary received a drug registration certificate for Levonorgestrel tablets from the National Medical Products Administration [3] - The approval is significant as it addresses the stable demand for emergency contraceptives, enhancing Renfu's product line and competitive position in the women's health medication market [3] Group 4 - Dairui Biotechnology's clinical trial application for RN3161, a GalNAc-siRNA targeting INHBE, has been accepted in Australia [4] - RN3161 aims to provide a long-term weight loss therapy for overweight and obese individuals, addressing urgent treatment needs and filling a market gap if successful [4] Group 5 - New Element Pharmaceuticals submitted a listing application to the Hong Kong Stock Exchange, with CITIC Securities as the sole sponsor [5] - The company focuses on developing therapies for metabolic, inflammatory, and cardiovascular diseases, with a promising product pipeline [5] - The listing is expected to accelerate research and market expansion, although the industry is highly competitive and poses significant development risks [5]